Allogene Therapeutics to Report Second Quarter Financial Results on August 4, 2021
July 27 2021 - 8:30AM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR
T (AlloCAR T™) therapies for cancer, today announced that it will
report second quarter 2021 financial results on Wednesday, August
4, 2021, after the close of the market. The announcement will be
followed by a live audio webcast and conference call at 2:00 PM
Pacific Time/5:00 PM Eastern Time.
Audio Webcast The webcast will be made
available on the Company's website at www.allogene.com under
the Investors tab in the News and Events section. Following the
live audio webcast, a replay will be available on the Company's
website for approximately 30 days.
Dial-In Information Live
(U.S. / Canada): 1 (866) 940-5062Live (International): 1
(409) 216-0618Conference ID: 8080137
About Allogene TherapeuticsAllogene
Therapeutics, with headquarters in South San Francisco, is a
clinical-stage biotechnology company pioneering the development of
allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies
for cancer. Led by a management team with significant experience in
cell therapy, Allogene is developing a pipeline of “off-the-shelf”
CAR T cell therapy candidates with the goal of delivering readily
available cell therapy on-demand, more reliably, and at greater
scale to more patients. For more information, please visit
www.allogene.com, and follow @AllogeneTx on Twitter and
LinkedIn.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes
of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. The press release may, in some cases, use terms
such as "predicts," "believes," "potential," "proposed,"
"continue," "estimates," "anticipates," "expects," "plans,"
"intends," "may," "could," "might," "will," "should" or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. Forward-looking statements
include statements regarding intentions, beliefs, projections,
outlook, analyses or current expectations concerning, among other
things: the ability to develop allogeneic CAR T therapies for
cancer and the potential benefits of AlloCAR T therapy. Various
factors may cause differences between Allogene’s expectations and
actual results as discussed in greater detail in Allogene’s filings
with the Securities and Exchange Commission (SEC), including
without limitation in its Form 10-Q for the quarter ended March 31,
2021. Any forward-looking statements that are made in this press
release speak only as of the date of this press release. Allogene
assumes no obligation to update the forward-looking statements
whether as a result of new information, future events or otherwise,
after the date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:Christine
CassianoChief Communications Officer(714)
552-0326Christine.Cassiano@allogene.com
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Apr 2023 to Apr 2024